You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Alum

Showing 176 - 199 of 199
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Coronavirus (SARS-CoV) Trial in Houston (Aluminum hydroxide, Placebo, SARS-CoV)

Withdrawn
  • Coronavirus (SARS-CoV)
  • Aluminum hydroxide
  • +2 more
  • Houston, Texas
    Baylor College of Medicine - Molecular Virology and Microbiology
Nov 29, 2012

Clostridium Infections Trial in Orlando, Lexington (Vaccine diluent buffer (Placebo), C. difficile toxoid vaccine (2 µg), C.

Completed
Has Results
  • Clostridium Infections
  • Vaccine diluent buffer (Placebo)
  • +3 more
  • Orlando, Florida
  • +1 more
Apr 9, 2012

Systems Biology, Early Gene, EV71 Vaccine Trial in Nanjing (320U /0.5ml, 0/0.5ml )

Completed
  • Systems Biology
  • +2 more
  • 320U /0.5ml
  • 0/0.5ml placebo
  • Nanjing, Jiangsu, China
    Jiangsu Provincial Center for Diseases Control and Prevention
May 7, 2013

Pneumococcal Infections Trial in Berlin (IC47)

Completed
  • Pneumococcal Infections
  • IC47
  • Berlin, Germany
    Parexel International GmbH, Institute for Clinical Pharmacology
Oct 18, 2012

HDL, Drug Safety Trial in Vienna (ATH03)

Completed
  • HDL
  • Drug Safety
  • ATH03
  • Vienna, Austria
    Department for Clinical Pharmacology Medical University Vienna
Oct 4, 2012

Type 1 Diabetes Trial in United States (rhGAD65, Placebo)

Terminated
  • Type 1 Diabetes Mellitus
  • Tucson, Arizona
  • +42 more
Oct 9, 2012

Alzheimer's Disease Trial in Vienna (AFFITOPE AD03, AFFITOPE AD03 + Alum)

Completed
  • Alzheimer's Disease
  • AFFITOPE AD03
  • AFFITOPE AD03 + Alum
  • Vienna, Austria
    MUW Wien
Dec 19, 2011

Allergy Trial in Vienna (Bet v 1aF1-Alum + Bet v 1aF2-Alum, Alum-Placebo)

Unknown status
  • Allergy
  • Bet v 1aF1-Alum + Bet v 1aF2-Alum
  • Alum-Placebo
  • Vienna, Austria
  • +1 more
May 12, 2011

Type 1 Diabetes Trial in Worldwide (rhGAD65, Placebo)

Terminated
  • Type 1 Diabetes Mellitus
  • Helsinki, Finland
  • +69 more
Oct 7, 2011

Healthy Trial in Tehran (Alum-ALM + BCG)

Completed
  • Healthy
  • Alum-ALM + BCG
  • Tehran, 14166, Iran, Islamic Republic of
    Center for Research & Training in Skin Diseases & Leprosy, TUMS
Feb 16, 2011

Sexually Transmitted Diseases, Viral Trial in London (Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads)

Completed
  • Sexually Transmitted Diseases, Viral
  • Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads
  • London, England, United Kingdom
    St George's Vaccine Institute, St George's University of London
Jan 26, 2011

HIV Trial in Milan, Rome (recombinant HIV-1 Tat protein)

Completed
  • HIV Infections
  • recombinant HIV-1 Tat protein
  • Milan, Italy
  • +3 more
Feb 28, 2011

HIV Trial in Milan, Rome (Biologically active recombinant Tat protein)

Completed
  • HIV Infections
  • Biologically active recombinant Tat protein
  • Milan, Italy
  • +3 more
Feb 28, 2011

Healthy Trial in Tehran (Alum-ALM + BCG)

Completed
  • Healthy
  • Alum-ALM + BCG
  • Tehran, Iran, Islamic Republic of
    Center for Research & Training in Skin Diseases & Leprosy
Nov 17, 2009

Influenza Trial in Leicester (H9N2 whole virus vaccine, IM, 1.5microg, H9N2 whole virus vaccine, IM, 5microg, H9N2 whole virus

Completed
  • Influenza
  • H9N2 whole virus vaccine, IM, 1.5microg
  • +13 more
  • Leicester, Leicestershire, United Kingdom
    University Hospitals Leicester
Jul 20, 2009

Prophylaxis Herpes Simplex Trial in Gent (Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141, Herpes simplex virus

Completed
  • Prophylaxis Herpes Simplex
  • Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141
  • Herpes simplex virus containing gD-Alum
  • Gent, Belgium
    GSK Clinical Trials Call Center
Jun 16, 2008

Healthy Trial in Paris (hepatitis B antigen (without alum) plus IMP321, hepatitis B antigen alone (without alum), Engerix B)

Completed
  • Healthy
  • hepatitis B antigen (without alum) plus IMP321
  • +2 more
  • Paris, France
    SGS Aster-Cephac
Apr 22, 2008

Plasmodium Falciparum Malaria Trial in Nijmegen, Rijswijk (PfAMA-1-FVO[25-545])

Completed
  • Plasmodium Falciparum Malaria
  • PfAMA-1-FVO[25-545]
  • Nijmegen, Netherlands
  • +1 more
Aug 7, 2008

Cutaneous Leishmaniasis Trial run by the NIAID (Combination of autoclaved leishmania antigen with recombinant human

Completed
  • Cutaneous Leishmaniasis
  • Combination of autoclaved leishmania antigen with recombinant human interleukin-12 (rhIL-12) and aluminum hydroxide gel as adjuvants
  • Bethesda, Maryland
    National Institute of Allergy and Infectious Diseases (NIAID)
Mar 3, 2008

Malaria Trial in Tubingen (GMZ2 (GLURP + MSP3 Hybrid) (malaria vaccine))

Unknown status
  • Malaria
  • GMZ2 (GLURP + MSP3 Hybrid) (malaria vaccine)
  • Tubingen, Germany
    Institut for Tropical Medicine, University of Tubingen
Aug 9, 2007

HIV Trial in Baltimore, Rochester (HIV-1 Peptide Vaccine, Microparticulate Monovalent)

Completed
  • HIV Infections
  • HIV-1 Peptide Vaccine, Microparticulate Monovalent
  • Baltimore, Maryland
  • +1 more
Jun 23, 2005

HIV Trial in United States (MN rgp120/HIV-1 and GNE8 rgp120/HIV-1, MN rgp120/HIV-1 and A244 rgp120/HIV-1, Aluminum hydroxide)

Completed
  • HIV Infections
  • MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
  • +2 more
  • Denver, Colorado
  • +3 more
Jun 23, 2005

HIV, HIV Seronegativity Trial in Worldwide (MN rgp120/HIV-1 and GNE8 rgp120/HIV-1)

Completed
  • HIV Infections
  • HIV Seronegativity
  • MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
  • Birmingham, Alabama
  • +66 more
Jun 23, 2005

HIV Trial in San Francisco (HIV-1 Peptide Vaccine, Microparticulate Monovalent, rgp120/HIV-1MN Monovalent Octameric V3 Peptide

Completed
  • HIV Infections
  • HIV-1 Peptide Vaccine, Microparticulate Monovalent
  • rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine
  • San Francisco, California
    Univ of California at San Francisco Gen Hosp
Jun 23, 2005